Medical Advocates
HCV Infection/Disease
 
Management
 
General Reports    
Directly Observed Therapy
Screening 
Pretreatment 
Drugs   
 Surgery  
Adherence        
Mental Health               
Nutrition/Weight Mngmt
Fatigue/Anemia
 		 Acute Hepatitis
 Recurrent Hepatitis
Chronic Hepatitis
HCV/HBV Coinfection
Non-Responders
Adverse Events
Alternative Therapies
Treatment Failure
Economics
Resources
 
HCV Main Page Main New/Newsworthy    Home Page    
Last Update:  January 29, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P.
J Viral Hepat. 2012 Jan;19 Suppl 1:7-13...
 Abstract

New developments in HCV therapy.
Kronenberger B, Zeuzem S.
J Viral Hepat. 2012 Jan;19 Suppl 1:48-51
 Abstract

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
Calvaruso V, Craxì A.
Liver Int. 2012 Feb;32 Suppl 1:2-8
 Abstract

Barriers to hepatitis C treatment.
McGowan CE, Fried MW.
 Liver Int. 2012 Feb;32 Suppl 1:151-6. .
 Abstract

The future for the treatment of genotype 4 chronic hepatitis C.
Esmat G, El Raziky M, El Kassas M,  et al
 Liver Int. 2012 Feb;32 Suppl 1:146-50..
 Abstract

Future treatment of patients with HCV cirrhosis.
Bourlière M, Khaloun A, Wartelle-Bladou C, et al
 Liver Int. 2012 Feb;32 Suppl 1:113-9.
Abstract

Optimization of Comorbidity Therapy to Achieve Sustained Viral Response in HCV Patients.
Ucciferri C, Vecchiet J, Pizzigallo E, Falasca K.
Hepatogastroenterology. 2011 Dec 22;59(117)..
 Abstract

Management of Hepatitis C in Patients with Chronic Kidney Disease.
Al-Freah MA, Zeino Z, Heneghan MA. et al
Curr Gastroenterol Rep. 2011 Dec 10.
 Abstract

Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C.
Hoefs JC, Aulakh VS, Ilagan BJ.
 Dig Dis Sci. 2011 Dec 4..
 Abstract

Treatment of Non-Genotype 1 Hepatitis C Virus Patients.
Mangia A, Mottola L.
 Curr Gastroenterol Rep. 2011 Nov 24..
 Abstract

General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting.
Lambert SM, Page AN, Wittmann J,  et al
 Aust J Prim Health. 2011;17(3):282-7.
 Abstract

Naives, Nonresponders, Relapsers: Who Is There Left to Treat?
Desai AP, Reau N.
 Clin Liver Dis. 2011 Aug;15(3):483-495..
 Abstract

Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1:
Options and Considerations.
Khalid O, Bacon BR.
 Clin Liver Dis. 2011 Aug;15(3):573-583..
 Abstract

FULL-TEXT ARTICLE
 Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst
a Population of Injecting Drug Users.
Martin NK, Pitcher AB, Vickerman P, et al  
PLoS One. 2011;6(8):e22309.
 Paper

FULL-TEXT ARTICLE
 Management of hepatitis C virus (HCV) infection in drug substitution programs.
Witteck A, Schmid P, Hensel-Koch K,  et al
Swiss Med Wkly. 2011 May 27;141:w13193
 Paper

'Knowledge, attitudes and behaviours associated with the provision of hepatitis C care
by Canadian family physicians.
Cox J, Graves L, Marks E, et al
J Viral Hepat. 2011 Jul;18(7):e332-40.
 Abstract

UKHCDO guidelines on the management of HCV in patients with hereditary bleeding
disorders 2011.
Wilde JT, Mutimer D, Dolan G,  et al
Haemophilia. 2011 Jun 9..
 Abstract

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers.
Arora S, Thornton K, Murata G,  et al
N Engl J Med. 2011 Jun 1.
 Abstract

Future perspective in the treatment of chronic hepatitis C.
Fernández-Montero JV, Soriano V.
Rev Esp Sanid Penit. 2011 Jun;13(1):21-29
 Abstract
Racial differences in hepatitis C treatment eligibility.
Melia MT, Muir AJ, McCone J, et al
 Hepatology. 2011 Apr 12.
Abstract

Five-year follow-up of patients with chronic C hepatitis and sustained virological response.
 Puig Del Castillo I, Miquel Planas M, et al
Rev Esp Enferm Dig. 2011 Feb;103(2):56-61..
 Abstract

Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for
management.
 Arends JE, Lambers FA, van der Meer JT,  et al
Neth J Med. 2011 Jan;69(1):43-9.
 Abstract

Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis.
Singal AK, Sagi S, Kuo YF, Weinman S
Eur J Gastroenterol Hepatol. 2011 Jan 20
 Abstract

Treatment of hepatitis C virus infection in patients with end-stage renal disease.
 Liu CH, Kao JH."
 J Gastroenterol Hepatol. 2011 Feb;26(2):228-239. ..
 Abstract

Hepatitis C - diagnostics and treatment.
 Dalgard O, Konopski Z, Bosse FJ,  et al
Tidsskr Nor Laegeforen. 2011 Jan 7;131(1):E1-E8
 Abstract

Current antiviral combination therapy for chronic hepatitis C patients who failed to
interferon alfa-based treatment.
 Trapero-Marugán M, Mendoza J,  et al
J Clin Pharm Ther. 2010 Dec 22.
Abstract

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone
maintenance therapy.
 Taylor LE, Bowman SE, Chapman S, Zaller N, et al
Drug Alcohol Depend. 2010 Dec 20.
Abstract

FULL-TEXT ARTICLE
Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected
Patients by Discriminate Analysis Using Viral and Host Factors
 Saludes V,  Bracho MA , Valero O, et al
PLoS One. 2010 Nov 30
 Paper

Hemodialysis of Patients with HCV Infection: Isolation Has a Definite Role.
 Agarwal SK
 Nephron Clin Pract. 2010 Nov 3;117(4):c328-c332
 Abstract

FULL-TEXT PDF ARTICLE
 Hepatitis C Treatment: current and future perspectives.
 Munir S, Saleem S, Idrees M, et al
Virol J. 2010 Nov 1;7(1):296.
Paper

IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection:
The Future of Personalized HCV Therapies.
 Clark PJ, Thompson AJ, McHutchison JG.
Am J Gastroenterol. 2010 Oct
Abstract

Factors associated with specialist assessment and treatment for hepatitis C virus
infection in New South Wales, Australia.
Grebely J, Bryant J, Hull P, et al
J Viral Hepat. 2010 Sep 14.
 Abstract

Development of the Hepatitis C Self-Management Program.
 Groessl EJ, Weingart KR, Gifford AL, et al
Patient Educ Couns. 2010 Jul 15
 Abstract

Predictors of Early Treatment Discontinuation Among Patients with Genotype 1
Hepatitis C and Implications for Viral Eradication.
Beste LA, Ioannou GN, Larson M, et al
Clin Gastroenterol Hepatol. 2010 Aug 5.
 Abstract

FULL-TEXT ARTICLE
 Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients:
an open-labelled comparison study.
 Gonvers J, Heim M, Cavassini M, et al
Swiss Med Wkly. 2010 Jul 19;140:w13055.
Paper

Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV.
Proeschold-Bell RJ, Blouin R, Reif S,  et al
South Med J. 2010 Jul;103(7):635-41.
 Abstract

Patient preferences and assessment of likely adherence to hepatitis C virus treatment.
Brett Hauber A, Mohamed AF, Beam C,  et al
J Viral Hepat. 2010 Jun 22.
 Abstract

Individualization of antiviral therapy for chronic hepatitis C.
 Teoh NC, Farrell GC, Chan HL.
J Gastroenterol Hepatol. 2010 Jul;25(7):1206-1216.
 Abstract

Major adverse cardiac events in patients with hepatitis C infection treated with bare-metal
versus drug-eluting stents.
Palaniswamy C, Aronow WS, Sukhija R, et al
Clin Cardiol. 2010 Jun;33(6):367-70
 Abstract

Gender influence on treatment of chronic hepatitis C genotype 1.
 Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, et al
Rev Soc Bras Med Trop. 2010 Jun;43(3):217-
 Abstract

Timing of hepatitis C antiviral therapy in patients with advanced liver disease:
a decision analysis model.
Saab S, Hunt DR, Stone MA,  et al
Liver Transpl. 2010 Jun;16(6):748-59
 Abstract

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual
Meeting of the Japan Society of Hepatology (2009).
Namiki I, Nishiguchi S, Hino K,.
Hepatol Res. 2010 Apr;40(4):347-68.
 Abstract

FULL-TEXT ARTICLE
 Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic
hepatitis C.
 Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R.
 World J Gastroenterol. 2010 Apr 14;16(14):1747-52
Paper

Institute of Medicine recommendations for the prevention and control of hepatitis B and C.
 Mitchell AE, Colvin HM, Palmer Beasley R
 Hepatology. 2010 Feb 22;51(3):729-733.
 Abstract

Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions o
f clients and health professionals.
Treloar C, Newland J, Rance J, Hopwood M.J
iral Hepat. 2010 Jan 13.
Abstract

New trends in hepatitis C management.
Mallet V, Vallet-Pichard A, Pol S.
Presse Med. 2010 Jan 12
 Abstract

Hepatitis C and diabetes: one treatment for two diseases?
 Pattullo V, Heathcote J
 .Liver Int. 2009 Dec 22.
Abstract

Reducing treatment duration in patients infected with hepatitis C genotype 1:
any need for further studies?
 Craxì A.
 Antivir Ther. 2009;14(8):1045-9.
 Abstract

Optimal length of antiviral therapy in patients with hepatitis C virus
genotypes 2 and 3: a meta-analysis.
 Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP.
 Antivir Ther. 2009;14(8):1139-48.
 Abstract

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).
 Kieffer TL, Kwong AD, Picchio GR.
 J Antimicrob Chemother. 2009 Nov 10
 Abstract

Hepatitis C treatment completion rates in routine clinical care.
 Butt AA, McGinnis KA, Skanderson M, Justice AC
 Liver Int. 2009 Nov 4.
 Abstract

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term
follow-up.
Corey KE, Kane E, Munroe C, et al
 Hepatology. 2009 Oct;50(4):1030-7
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Feasibility of individualized treatment for hepatitis C patients in the real world.
Chen TM, Huang PT, Lin CH, et al
J Gastroenterol Hepatol. 2009 Sep 25
 Abstract

FULL-TEXT ARTICLE
 Minimizing cardiac surgery risks in a Hepatitis C patient: Changing surgical strategy after
evaluation by modern imaging technologies.
 Kur F, Beiras-Fernandez A, Oberhoffer M, et al
Ther Clin Risk Manag. 2009 Aug;5(4):409-12
 Paper

Reduction in Neutrophil Count During Hepatitis C Treatment: Drug Toxicity or Predictor
of Good Response?
Alvarez-Uria G, Day JN, Nasir AJ, et al
 Dig Dis Sci. 2009 Sep 16.
 Abstract

Hepatitis C: recent successes and continuing challenges in the development of improved treatment
modalities.
Shimakami T, Lanford RE, Lemon SM.
Curr Opin Pharmacol. 2009 Sep 15.
 Abstract

Hepatitis C therapy-the future looks bright.
 Qureshi SA, Qureshi H, Hameed A.
 Eur J Clin Microbiol Infect Dis. 2009 Aug 29
 Abstract

Patients' Preferences for Treatment of Hepatitis C.
 Fraenkel L, Chodkowski D, Lim J, Garcia-Tsao G.
Med Decis Making. 2009 Jul 27.
 Abstract

Treatment of chronic hepatitis C in polytransfused thalassaemic patients:
a meta-analysis.
 Alavian SM, Tabatabaei SV.
 J Viral Hepat. 2009 Jul 23.
 Abstract

Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake
needs a critical view.
 Treloar CJ, Fraser SM.
Drug Alcohol Rev. 2009 Jul;28(4):436-40.
 Abstract

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type
1-infected patients.
Berg T, Weich V, Teuber G, et al
 Hepatology. 2009 Apr 6.
 Abstract

The multidimensional burden of hepatitis C and its treatment: a case study.
Taylor-Young P, Hildebrandt E.
Gastroenterol Nurs. 2009 May-Jun;32(3):180-7.
 Abstract

Current and future treatment options for HCV.
Kronenberger B, Zeuzem S. 
Ann Hepatol. 2009 Apr-Jun;8(2):103-12
 Abstract

Eradication of hepatitis C virus after a 5-week treatment
 Gaundong Mbéthé GL, Foucher J, Deledinghen V, Couzigou VP.
Rev Med Interne. 2009 May 18
 Abstract

FULL-TEXT ARTICLE
Immune-based therapy for chronic hepatitis C.
 Chang DY, Shin EC.
J Leukoc Biol. 2009 Apr 24.
 Paper

Evaluation of immigration status, race and language barriers on chronic hepatitis C virus
infection management and treatment outcomes.
 Giordano C, Druyts EF, Garber G, Cooper C. 
Eur J Gastroenterol Hepatol. 2009 Mar 21.
 Abstract
 
Future treatment options for HCV: double, triple, what is the optimal combination?
 Kronenberger B, Zeuzem S.
Best Pract Res Clin Gastroenterol. 2008;22(6):1123-36.
 Abstract
 
Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients:
implications for hepatitis C treatment.
 Brener L, Treloar CJ.
Aust Health Rev. 2009 Feb 1;33(1):100-106
 Abstract

A review of current anti-HCV treatment regimens and possible future strategies.
 Neukam K, Macías J, Mira JA, Pineda JA. 
Expert Opin Pharmacother. 2009 Feb;10(3):417-33.
 Abstract
 
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
 Tillmann HL, Patel K, McHutchison JG.
Curr Gastroenterol Rep. 2009 Feb;11(1):5-14.
 Abstract
 
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
 Kronenberger B, Zeuzem S. 
Curr Gastroenterol Rep. 2009 Feb;11(1):15-21
 Abstract
.
Reduction of Hepatitis C Virus Using Lectin Affinity Plasmapheresis in Dialysis Patients.
 Tullis RH, Duffin RP, Handley HH, et al
Blood Purif. 2009;27(1):64-69.
Abstract
 
Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase.
Kumada T, Toyoda H, Kiriyama S, et al
 J Med Virol. 2009 Jan 16;81(3):446-451
 Abstract
 
What is the safe duration of therapy for patients infected with HCV genotype 6?
 Antaki N, Marcellin P.
Nat Clin Pract Gastroenterol Hepatol. 2008 Dec 17
 Abstract
 
Management of hepatitis C and fatty liver: a consciousness survey among gastroenterologists
and general internists.
 Okanoue T, Shima T, Mizuno M, et al
Nippon Shokakibyo Gakkai Zasshi. 2008 Dec;105(12):1737-48
 Abstract
 
What is on the horizon for treatment of chronic hepatitis C?
 Bergmann JF, De Knegt RJ, Janssen HL.
Minerva Med. 2008 Dec;99(6):569-82.
 Abstract
 
Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients.
Ladero JM.
 Ann Hepatol. 2008 Oct-Dec;7(4):392-4.
 Abstract
 
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors
in treatment-naïve patients.
 Kuntzen T, Timm J, Berical A, et al  
Hepatology. 2008 Dec;48(6):1769
 Abstract
 
Management of hepatitis C and fatty liver: a consciousness survey among gastroenterologists and
general internists.
 Okanoue T, Shima T, Mizuno M,  et al
 Nippon Shokakibyo Gakkai Zasshi. 2008 Dec;105(12):
 Abstract
 
Optimizing dosage and duration therapy for chronic hepatitis C difficult-to-treat patients.
Ladero JM.
 Ann Hepatol. 2008 Oct-Dec;7(4):392-4.
 Abstract
 
Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C
infection.
 McGovern BH, Abu Dayyeh BK, Chung RT.
Hepatology. 2008 Nov;48(5):1700-12
 Abstract
 
Perspectives in therapy for hepatitis C.
 Vento S, Cainelli F, Temesgen Z.
Expert Opin Investig Drugs. 2008 Nov;17(11):1635-1639.
 Abstract
 
The role of obstetrician/gynecologists in the management of hepatitis C virus infection.
 Gonik B.  
Infect Dis Obstet Gynecol. 2008;2008:374517
 Abstract
 
Expert opinion on the treatment of patients with chronic hepatitis C.
 Zeuzem S, Berg T, Moeller B,et al 
J Viral Hepat. 2008 Aug 28.
 Abstract
 
Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment
response and managing adverse events.
 Smith JP.
 Pharmacotherapy. 2008 Sep;28(9):1151-61
 Abstract
 
Treatment regimens for patients with chronic hepatitis C.
 Trapero-Marugan M, González-Moreno L, Chaparro-Sánchez M, et al
 Minerva Gastroenterol Dietol. 2008 Jun;54(2):209-17
 Abstract
 
Hepatitis C for addiction professionals
 Sylvestre D.  
Addict Sci Clin Pract. 2007 Dec;4(1):34-41
 Abstract
 
Targeting lipid metabolism in the treatment of hepatitis C virus infection.
 Amemiya F, Maekawa S, Itakura Y, et al   
J Infect Dis. 2008 Feb 1;197(3):361-70
 Abstract
 
How Physicians Describe Outcomes to HCV Therapy: Prevalence and Meaning of "Cure" During
Provider-Patient In-office Discussions of HCV.
 Hamilton HE, Gordon C, Nelson M, et al 
J Clin Gastroenterol. 20
Abstract
 
FUKLL-TEXT PDF ARTICLE
 Making it happen: managed care considerations in vanquishing hepatitis C.
McHutchison JG, Bacon BR, Owens GS. et al 
Am J Manag Care. 2007 Dec;13 Suppl 12:S327-36;
Paper
 
An introduction of the consensus statements on the diagnosis, management and treatment of
hepatitis C virus infection from the Asian Pacific Association for the Study of the Liver.
 Li L, Fan HB, Yang DL.
Zhonghua Gan Zang Bing Za Zhi. 2007 Dec;15(12):955-7.
 Abstract
 
Inflammation and Repair in Viral Hepatitis C.
 Neuman MG, Sha K, Esguerra R, et al 
Dig Dis Sci. 2007 Nov 10;
 Abstract
 
Improved cognitive function as a consequence of hepatitis C virus treatment.
Thein H, Maruff P, Krahn M, et al
HIV Med. 2007 Nov;8(8):520-8
 Abstract
 
FULL TEXT ARTICLE
Specifically targeted antiviral therapy for hepatitis C virus.
 Parfieniuk A, Jaroszewicz J, Flisiak R, et al  
World J Gastroenterol. 2007 Nov 21;13(43):5673-81.
 Paper
 
FULL TEXT ARTICLE
 Clinical significance of activity of ALT enzyme in patients with hepatitis C virus.
 Akkaya O, Kiyici M, Yilmaz Y, et al
World J Gastroenterol. 2007 Nov 7;13(41):5481-5.
 Paper
 
Treatment uptake and outcomes among current and former injection drug users receiving
directly observed therapy within a multidisciplinary group model for the treatment of hepatitis
C virus infection.
 Grebely J, Genoway K, Khara M, et al
Int J Drug Policy. 2007 Oct;18(5):437-43.
 Abstract
 
Integrating multiple programme and policy approaches to hepatitis C prevention and care for
injection drug users: a comprehensive approach.
Birkhead GS, Klein SJ, Candelas AR, et al  
Int J Drug Policy. 2007 Oct;18(5):417-25
 Abstract
 
Improving access to HCV treatment: external jugular venepuncture can overcome problems
with difficult venous access.
Mason S, Watts A, Sheils S, Koorey D.
Int J Drug Policy. 2007 Oct;18(5):433-6.
 Abstract
 
A Preliminary Comparison of Major Kinds of Obstacles to Enrolling in Substance Abuse Treatment
(AOD) Reported by Injecting Street Outreach Clients and Other Stakeholders.
Appel PW, Oldak R.
Am J Drug Alcohol Abuse. 2007;33(5):699-705.
Abstract
 
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of
liver-related complications.
 Pradat P, Tillmann HL, Sauleda S, et al 
J Viral Hepat. 2007 Aug;14(8):556-63
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL TEXT ARTICLE
 Hepatitis C virus: Virology, diagnosis and management of antiviral therapy.
 Chevaliez S, Pawlotsky JM.
World J Gastroenterol. 2007 May 7;13(17):2461-6
 Paper
 
A Systematic Review of Provider Knowledge of Hepatitis C: Is it Enough for a Complex
Disease?
 Zickmund SL, Brown KE, Bielefeldt K.
 Dig Dis Sci. 2007 Apr 4;
 Abstract
 
Treatment of hepatitis C virus infection.
 Weigand K, Stremmel W, Encke J  
World J Gastroenterol. 2007 Apr 7;13(13):1897-905
 Abstract
 
Short-duration therapy for hepatitis C: suitable for all?
 Mangia A.
J Viral Hepat. 2007 Apr;14(4):221-7.
 Abstract
 
Hepatitis C management by addiction medicine physicians: Results from a national survey.
 Litwin AH, Kunins HV, Berg KM, et al
J Subst Abuse Treat. 2007 Mar 20
 Abstract
 
New paradigms in the management of hepatitis C virus co-infections.
 Sherman KE.  
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S10-6.
 Abstract
 
Medical care and alcohol use after testing hepatitis C antibody positive at STD clinic
and HIV test site screening programs.
 Mark KE, Murray PJ, Callahan DB, Gunn RA.
Public Health Rep. 2007 Jan-Feb;122(1):37-43.
 Abstract
 
Short-term treatment duration for HCV-2 and HCV-3 infected patients.
 Andriulli A, Dalgard O, Bjoro K, Mangia A.  
Dig Liver Dis. 2006 Aug 14
 Abstract
 
FULL-TEXT ARTICLE
Advances in Managing Hepatitis C Virus (HCV) Infection
Hu KQ.  
Int J Med Sci. 2006;3(2):28.
 Paper
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 A practical approach to managing patients with HCV infection.
 Huang RH, Hu KQ. 
Int J Med Sci. 2006;3(2):63-8.
 Paper
 
Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.
 Hare CB, Morris JA, Chu A, Gotz V, rt al
Pharmacoepidemiol Drug Saf. 2005 Sep 1;
Abstract
 
Treatment of hepatitis C: critical appraisal of the evidence.
 Camma C, Licata A, Cabibbo G, et al 
Expert Opin Pharmacother. 2005 Mar;6(3):399-408.
Abstract
 
Prospective study in 142 cases of hepatitis C virus infection.
 Fan WM, Zhu WF, Yin LM, et al
World J Gastroenterol. 2004 Oct 1;10(19):2867-9
 Abstract
 
Hepatitis C treatment update.
 Pearlman BL. 
Am J Med. 2004 Sep 1;117(5):344-5
 Abstract
 
The impact of hepatitis C status on postoperative outcome.
Cheung RC, Hsieh F, Wang Y, Pollard JB.
Anesth Analg. 2003 Aug;97(2):550-4.
 Abstract

Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy.
 Isaguliants MG.
Curr Pharm Biotechnol 2003 Jun;4(3):169-83
 Abstract
 
Directly Observed Therapy
 
    Journal Papers, Abstracts, and Commentaries
 
  Directly observed therapy for the treatment of hepatitis C virus infection in current and
former injectiondrug users.
 Grebely J, Raffa JD, Meagher C, et al 
J Gastroenterol Hepatol. 2007 Jul 20;
Abstract
Screening
 
    Journal Papers, Abstracts, and Commentaries
 
  Is screening for interferon retinopathy in hepatitis C justified?
 Cuthbertson FM, Davies M, McKibbin M. 
Br J Ophthalmol. 2004 Dec;88(12):1518-1520.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  Importance of screening colonoscopy among patients with hcv related liver disease
Chaparala H., Gurakar A., Wright H.,, et al
(Conference Citations from the 12th International Symposium on Viral Hepatitis and Liver Disease)
 Abstract
Pretreatment
 
    Journal Papers, Abstracts, and Commentaries
 
  Pretreatment sequence diversity differences in the full-length Hepatitis C Virus open reading
frame correlate with early response to therapy.
 Donlin MJ, Cannon NA, Yao E, et al
J Virol. 2007 May 23;
 Abstract
Adherence to Drug Therapy
 
    Journal Papers, Abstracts, and Commentaries
 
 
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life,
observational study.
 Marcellin P, Chousterman M, Fontanges T,  et al
 Liver Int. 2011 Apr;31(4):516-524
 Abstract

The effect of adherence to therapy on sustained response in daily or three times a week "
interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C
patients.
Raptopoulou M, Tsantoulas D, Vafiadi I, et al 
J Viral Hepat. 2005 Jan;12(1):91-5
 Abstract
 
Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.
Mulhall BP, Younossi Z.
J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S23-7
 Abstract

Adherence to combination therapy: influence on sustained virologic response and
economic mpact.
Manns MP.
 Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S11-24.
 Abstract
 
Adherence to combination therapy enhances sustained response in genotype-1-
infected patients with chronic hepatitis C.
 McHutchison JG, Manns M, Patel K, et al.
Gastroenterology 2002 Oct;123(4):1061-9
 Abstract

Mental Health Challenges
 
    Journal Papers, Abstracts, and Commentaries
 
 
Management of patients with hepatitis C by French psychologists and psychiatrists:
A practical investigation.
 Lang JP, Schoeffler M, Michel L, et al
Gastroenterol Clin Biol. 2009 Nov 24
Abstract
 
Managing depression during hepatitis C treatment.
 Sockalingam S, Abbey SE.
Can J Psychiatry. 2009 Sep;54(9):614-25
 Abstract

Management of psychiatric disorders and addictive behaviors in patients with viral hepatitis C
in France.
 Lang JP, Michel L, Melin P, Schoeffler M, et al
Gastroenterol Clin Biol. 2009 Jan 7.
 Abstract
 
Gastroenterologists' perceptions of need and availability of psychiatric services for patients
with hepatitis C.
 Gleason O, Fucci J, Yates W.
Psychosomatics. 2008 Mar-Apr;49(2):132-6.
 Abstract

Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral
treatment evaluation and outcomes.
Knott A, Dieperink E, Willenbring ML, et al
 Am J Gastroenterol. 2006 Oct;101(10):2254-62.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  Depression Changes in Hepatitis C Patients Undergoing Antiviral Therapy
 KM Simpson, A Verma, DM Evon, et al
(136th APHA)
 Abstract
Nutrition/Weight Management
 
     Journal Papers, Abstracts, and Commentaries
 
 
Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in
patients with chronic hepatitis C virus.
Iwasa M, Iwata K, Kaito M, et al
Nutrition. 2004 Apr;20(4):368-71
 Abstract
 
Modest weight loss and physical activity in overweight patients with chronic liver
disease results in sustained improvements in alanine aminotransferase, fasting insulin,
and quality of life.
 Hickman IJ, Jonsson JR, Prins JB, et al 
Gut. 2004 Mar;53(3):413-419.
 Abstract
 
FULL-TEXT ARTICLE
Hepatitis C: Nutrition Care Canadian Guidelines for Health Care Providers.
 Can J Diet Pract Res. 2003 Autumn;64(3):139-141
 Paper
Fatigue/Anemia
 

     Journal Papers, Abstracts, and Commentaries

 
Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without
chronic hepatitis C.
Rabkin JG, McElhiney MC, Rabkin R.
 Int J STD AIDS. 2011 Feb;22(2):95-101.
 Abstract

Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients
with hepatitis C
Lunel-Fabiani F, Fouchard-Hubert I, Gergely AE.
Pathol Biol (Paris). 2003 Oct;51(8-9):520-4.
 Abstract

The experience of fatigue for people living with hepatitis C.
Glacken M, Coates V, Kernohan G, Hegarty J.
J Clin Nurs 2003 Mar;12(2):244-52
 Abstract

Fatigue in patients with chronic hepatitis C.
 Poynard T, Cacoub P, Ratziu V, et al.
 J Viral Hepat 2002 Jul;9(4):295-303
 Abstract

Fatigue, depression and chronic hepatitis C infection.
 Wessely S, Pariante C.
 Psychol Med 2002 Jan;32(1):1-10/
 Abstract
 
Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus
infection.
 Obhrai J, Hall Y, Anand BS.
J Clin Gastroenterol 2001 May-Jun;32(5):413-7
 Abstract
 
Acute Hepatitis
 

     Journal Papers, Abstracts, and Commentaries

 
Treatment of acute hepatitis C infection in HIV-infected patients.
Boesecke C, Rockstroh JK.
 Curr Opin HIV AIDS. 2011 Apr 23.
 Abstract

Treatment of acute HCV infection.
 Grebely J, Matthews GV, Dore GJ.
Nat Rev Gastroenterol Hepatol. 2011 Mar 22.
 Abstract

Management of Acute Hepatitis C.
 Maheshwari A, Thuluvath PJ.  
 Clin Liver Dis. 2010 Feb;14(1):169-176.
 Abstract

Therapy of acute hepatitis C: a review of literature.
 Santantonio T, Fasano M.
 Curr Pharm Des. 2008;14(17):1686-9.
 Abstract
 
Outcomes and Treatment of Acute Hepatitis C Virus Infection in a United States Population.
 Corey KE, Ross AS, Wurcel A, et al  
Clin Gastroenterol Hepatol. 2006 Aug 21;
 Abstract

Therapy of acute hepatitis C.
Alberti A, Boccato S, Vario A, Benvegnu L.
Hepatology 2002 Nov;36(5 Suppl 1):S195-200
 Abstract

Management strategies using pharmacogenomics in patients with severe HCV-1b infection:
A decision analysis.
Moriguchi H, Uemura T, Kobayashi M, et al.
Hepatology 2002 Jul;36(1):177-185
 Abstract

FULL-TEXT ARTICLE
ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis
Ryder SD,  Beckingham IJ
 BMJ 2001; 322: 151-153.
Paper

  

     Conference Reports, Abstracts, and Posters

 

Draft NIH Consensus Statement on the Management of Hepatitis C
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
Patients With Normal ALT Levels
 Bacon BR
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
Therapy of Acute Hepatitis C
 Alberti A
[NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
Side Effects of Therapy and Management
 Fried MW
[NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

Recurrent Hepatitis
Post-Transplant HCV Recurrence

     Journal Papers, Abstracts, and Commentaries

 
Transfusion has no effect on recurrence in hepatitis C after liver transplantation.
Rice MJ, Wendling A, Firpi RJ, et al
Acta Anaesthesiol Scand. 2010 Nov;54(10):1224-32.
Abstract

How can we identify better those with recurrent hepatitis C who will respond to therapy?
What are the optimal treatment regimen and treatment duration?
 Wright TL.
 Liver Transpl. 2003 Nov;9(11):S109-13.
 Abstract

Treatment of recurrent hepatitis C.
 Gane E
Liver Transpl 2002 Oct;8(10 Suppl 1):S28-37
 Abstract

  
Chronic Hepatitis
 
     Journal Papers, Abstracts, and Commentaries 
 
 
FULL-TEXT ARTICLE
 Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes.
Teng CJ, Liu HT, Liu CY, et al
Clinics (Sao Paulo). 2011;66(12):2055-61

Treatment of chronic hepatitis C virus infection. A study of best predictors for response
Ospina N, Rodríguez JL, Hernández M, et al
Rev Esp Quimioter. 2011 Dec;24(4 .
 Abstract

New treatments for chronic hepatitis C virus infection.
 Corouge M, Pol S.
Med Mal Infect. 2011 Jul 15.
 Abstract

Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
 Chevaliez S, Asselah T.
Clin Res Hepatol Gastroenterol. 2011 Jun;35 .
 Abstract

FULL-TEXT PDF ARTICLE
Thyroid disease is a favorable prognostic factor in achieving sustained virologic response
in chronic hepatitis C undergoing combination therapy: A nested case control study..
 Tran HA, Jones TL, Gibson R, Reeves GE.
 BMC Endocr Disord. 2011 May 24;11(1):10
 Paper

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
 Masarone M, Persico M.
 Expert Rev Anti Infect Ther. 2011 May;9(5):535-43..
 Abstract

A new standard of care for the treatment of chronic HCV infection.
Hofmann WP, Zeuzem S.
Nat Rev Gastroenterol Hepatol. 2011 Apr 5
 Abstract

Current therapies for chronic hepatitis C.
Ferguson MC.
Pharmacotherapy. 2011 Jan;31(1):92-111.
 Abstract

Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
Martín-Carbonero L, Tuma P,  et al
J Viral Hepat. 2010 Aug 31
 Abstract

Quality of care in patients with chronic hepatitis C virus infection: a cohort study.
 Kanwal F, Schnitzler MS, Bacon BR, et al
Ann Intern Med. 2010 Aug 17;153(4):231-9
 Abstract

Impact of international consensus guidelines on antiviral therapy of chronic hepatitis
C patients in Switzerland.
 Overbeck K, Dufour JF, Müllhaupt B, et al
Swiss Med Wkly. 2010 Feb 3
 Abstract

Antiviral completion rates and sustained viral response in hepatitis C patients with and
without preexisting major depressive disorder.
 Hauser P, Morasco BJ, Linke A, et al
Psychosomatics. 2009 Sep-Oct;50(5):500-5
Abstract

Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.
Gaglio PJ.
Nat Rev Gastroenterol Hepatol. 2009 Jun;6(6):372-5.
 Abstract

Treatment of chronic hepatitis C in hemodialysis patients.
Berenguer M.
Hepatology. 2008 Jul 28;48(5):1690-1699.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
 de Bruijne J, Buster EH, Gelderblom HC, et al 
Neth J Med. 2008 Jul-Aug;66(7):311-22.
 Paper
 
 
FULL TEXT ARTICLE
Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it.
 Pearlman BL
 World J Gastroenterol. 2008 Jun 21;14(23):3621-7
 Paper
 
Treatment of chronic viral hepatitis
 Pedersen C, Pedersen CR.
Ugeskr Laeger. 2008 Jun 9;170(24):2137-40.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C.
 Maylin S, Martinot-Peignoux M, Moucari R, et al
Gastroenterology. 2008 May 21.
Abstract
 
Rapid virologic response: a new milestone in the management of chronic hepatitis C
 Poordad F, Reddy KR, Martin P.
Clin Infect Dis. 2008 Jan 1;46(1):78-84
 Abstract
 
Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus
nonpatient factors.
 Kanwal F, Hoang T, Spiegel BM, et al
Hepatology. 2007 Nov 28;46(6):1741-1749
 Abstract
 
Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize
treatment duration as a function of viral genotype?
 Nguyen-Khac E, Capron D, Castelain S, et al
 Eur J Intern Med. 2007 Nov;18(7):510-5.
 Abstract
 
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment
with the'accordion' regimen?
 Marcellin P, Heathcote EJ, Craxì A.
J Hepatol. 2007 Oct;47(4):580-587.
 Abstract
 
Chronic hepatitis C virus infection: A review for pharmacists.
 Rodis J.
J Am Pharm Assoc (2003). 2007 Jul-Aug;47(4)
 Abstract
 
Maintenance therapy for chronic hepatitis C.
 Trépo C, Marion-Audibert AM, Samuel D, Guyader D, Fontanges T.
 Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 3):29-33.
Abstract
 
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
Westin J, Ydreborg M, Islam S, et al
Scand J Gastroenterol. 2007 Sep 18;:1-8
Abstract
 
Response prediction and treatment tailoring in chronic hepatitis C virus genotype 1 infection.
 Lindh M, Alestig E, Arnholm B, et al 
J Clin Microbiol. 2007 Jun 20;
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do
They Alter Their Decision with Time?
 Khokhar OS, Lewis JH
Dig Dis Sci. 2007 Mar 15;
 Abstract
 
Customizing treatment to patient populations.
 Brown RS Jr.
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S3-9.
 Abstract
 
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons
from the HALT-C trial.
 Everson GT, Hoefs JC, Seeff LB, et al 
Hepatology. 2006 Dec;44(6):1675-84.
 Abstract
 
Review article: management of patients with chronic hepatitis C virus infection and 'normal'
alanine aminotransferase activity.
 Zeuzem S, Alberti A, Rosenberg W, et al 
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1133-49.
 Abstract
 
Difficult-to-treat patients with chronic hepatitis C
 Zeuzem S. 
Schweiz Rundsch Med Prax. 2006 Sep 20;95(38):1459-64.
 Abstract
 
Recent development of therapeutics for chronic HCV infection.
 Huang Z, Murray MG, Secrist JA 3rd. et al 
Antiviral Res. 2006 Jun 23;
Abstract
 
Impact of obesity on treatment of chronic hepatitis C.
 Charlton MR, Pockros PJ, Harrison SA.
 Hepatology. 2006 May 25;43(6):1177-1186
 Abstract
 
Individualised treatment of chronic hepatitis C.
 Zeuzem S.
 Internist (Berl). 2006 Apr 7;
Abstract
 
Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients
with chronic hepatitis C.
 Moncoucy X, Leymarie F, Delemer B, et al
Gastroenterol Clin Biol. 2005 Apr;29(4):339-45.
Abstract
 
Persistence of hepatitis C virus after successful treatment of chronic hepatitis C:
Is hepatitis C infection for life?
 Radkowski M, Laskus T.   
Liver Transpl. 2004 Dec 22;11(1):114-116
Abstract
 
Co-occurring Hepatitis C, Substance Use, and Psychiatric Illness: Treatment Issues and
Developing Integrated Models of Care.
 Sylvestre DL, Loftis JM, Hauser P, et al
J Urban Health. 2004 Dec;81(4):719-34.
 Abstract
 
Current Treatment for Chronic Hepatitis C.
 Ferenci P.
 Curr Treat Options Gastroenterol. 2004 Dec;7(6):491-499
 Abstract
 
Prediction of treatment outcome in patients with chronic hepatitis C: Significance
of baseline parameters and viral dynamics during therapy.
 Berg T, Sarrazin C, Herrmann E, et al.
 Hepatology 2003 Mar;37(3):600-609
 Abstract
 
Therapy of chronic hepatitis C: a critical review.
 Saracco G, Olivero A, Ciancio A, et al.  
 Curr Drug Targets Infect Disord 2003 Mar;3(1):25-32
 Abstract
 
Treatment of chronic hepatitis C in nonresponders to previous therapy.
 Dantzler TE, Lawitz EJ.
Curr Gastroenterol Rep 2003 Feb;5(1):78-85
Abstract
 
Retreatment of patients with chronic hepatitis C.
 Shiffman ML.  
 Hepatology 2002 Nov;36(5 Suppl 1):S128-34
Abstract
 
High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C
patients naive to therapy.
 Abbas Z, Hamid S, Tabassum S.
 J Gastroenterol Hepatol 2002 May;17(5):577-581
Abstract

Approach to the patient with chronic hepatitis C virus infection.
 Herrine SK
Ann Intern Med 2002 May 21;136(10):747-57
Abstract

Management issues in chronic viral hepatitis: Hepatitis C.
 Sievert W.
 J Gastroenterol Hepatol 2002 Apr;17(4):415-22
 Abstract
 
FULL-TEXT ARTICLE
Regular review: Treatment of chronic hepatitis
Gow PJ , Mutimer D
BMJ 2001
Paper
 
FULL-TEXT ARTICLE
 ABC of diseases of liver, pancreas, and biliary system: Chronic viral hepatitis
Ryder SD,  Beckingham  IJ
 BMJ 2001
Paper
 
FULL-TEXT ARTICLE
Chronic viral hepatitis C: management update.
 Gutfreund KS, Bain VG.
CMAJ 2000 Mar 21;162(6):827-33
 Paper
 
 
     Conference Reports, Abstracts, and Posters
 
 

Draft NIH Consensus Statement on the Management of Hepatitis C
[NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
 Patients With Advanced Disease
 Wright, TL
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
Retreatment of Patients With Chronic Hepatitis C
 Shiffman ML
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

PRESENTATION
Side Effects of Therapy and Management
 Fried MW
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002 ]
 Report

Non-Responders
 
     Journal Papers, Abstracts, and Commentaries
 
 
Management of nonresponsive hepatitis C.
 Bailly F, Ahmed SN, Pradat P, Trepo C.
 Expert Rev Anti Infect Ther. 2010 Apr;8(4):379-95
 Abstract

Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of
Low Systemic Interferon Concentrations?
Alsiö A, Christensen PB, Färkkilä M,  et al
 Clin Infect Dis. 2010 Jan 20
 Abstract

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon
alfa plus ribavirin.
 Dieterich DT, Rizzetto M, Manns MP.
J Viral Hepat. 2009 Dec;16(12):833-43.
 Abstract

Treatment Options for Patients With Chronic Hepatitis C Not Responding to Initial Antiviral Therapy.
Jacobson IM.
Clin Gastroenterol Hepatol. 2009 Apr 9
 Abstract

HCV non-responder patients: definition of non response and treatment strategy.
 Marcellin P, Bourlière M, Pawlotsky JM, Ouzan D.  
Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 3):13-9.
 Abstract

Non-responders to previous treatment for hepatitis C.
 Gross JB. 
Minerva Gastroenterol Dietol. 2005 Mar;51(1):47-54.
 Abstract
 
HCV/HBV Coinfection
 

     Journal Papers, Abstracts, and Commentaries

  Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus coinfection.
Perumalswami PV, Bini EJ.
Minerva Gastroenterol Dietol. 2006 Jun;52(2):145-55.
Abstract		  
Adverse Events: General
 
     Journal Papers, Abstracts, and Commentaries
 
 

Metabolic alterations and chronic hepatitis C: treatment strategies.
 Adinolfi LE, Restivo L, Zampino R, et al
Expert Opin Pharmacother. 2011 Sep 2.
 Abstract

FULL-TEXT ARTICLE
 Management of Hepatitis C Antiviral Therapy Adverse Effects.
 Sung H, Chang M, Saab S.
Curr Hepat Rep. 2011 Mar;10(1):33-40.
 Paper

Management of Hepatitis C Antiviral Therapy Adverse Effects.
Sung H, Chang M, Saab S.
Curr Hepat Rep. 2011 Mar;10(1):33-40..
 Abstract

Sustained Virologic Response Decreases Serum Markers of Angiogenesis, Inflammation, and
Fibrosis in HIV/HCV-Coinfected Patients on Hepatitis C Virus Therapy
 García-Álvarez M, Berenguer J, Micheloud D, et al
AIDS Patient Care STDS. 2011 Feb 6.
 Abstract

Major Adverse Cardiac Events in Patients With Hepatitis C Infection Treated With
Bare-Metal Versus Drug-Eluting Stents.
Palaniswamy C, Aronow WS, Sukhija R,  et al
Clin Cardiol. 2010 Jun 15;33(6):367-370
 Abstract

Mortality in hepatitis C-positive patients treated with peritoneal dialysis.
 Wang SM, Liu JH, Chou CY, et al 
Perit Dial Int. 2008 Mar-Apr;28(2):183-7.
 Abstract

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of
liver-related complications.
 Pradat P, Tillmann HL, Sauleda S, et al 
J Viral Hepat. 2007 Aug;14(8):556-63
 Abstract
Alternative Therapies
 
     Journal Papers, Abstracts, and Commentaries
 
  Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against
Cirrhosis (HALT-C) Trial
 Seeff LB, Curto TM, Szabo G, et al 
Hepatology. 2007 Dec 21
 Abstract
Treatment Failure
 
     Journal Papers, Abstracts, and Commentaries
 
  Hepatitis C: which strategy in case of treatment failure ?
Bronowicki JP, Larrey D, Tran A, et al
 Gastroenterol Clin Biol. 2008 Mar;32(3 Pt 2):S109-16.
 Abstract
Economics
 
      Journal Papers, Abstracts, and Commentaries
 
   

Economic evaluation of early monotherapy versus delayed monotherapy or combination
therapy in patients with acute hepatitis C in Germany.
 Dintsios CM, Haverkamp A, Wiegand J, et al
Eur J Gastroenterol Hepatol. 2009 Jun 22.
Abstract
Resources
 

HCV Main Page Main New/Newsworthy    Home Page    

HCV Management